Argenx Unnatural Products acquisition pays 550 million dollars upfront for macrocyclic peptides
Argenx will pay $550 million upfront and up to $595 million in milestones for Santa Cruz peptide developer Unnatural Products. No programs, targets or clinical candidates were disclosed, and closing is expected by the end of 2026.
What's new
Argenx agreed on November 9, 2026 to acquire Santa Cruz macrocyclic peptide developer Unnatural Products for $550 million upfront and up to $595 million in milestones, a potential total of about $1.15 billion.
Why it matters
The deal moves an antibody focused immunology company into oral and long acting peptide discovery, following FDA approvals of oral peptides such as Icotyde and Lipfendra in 2026.
What's next
Argenx expects the deal to close by the end of 2026. No programs, targets or clinical candidates have been disclosed, so the next signal would be a named program or a first human study.
Argenx has agreed to buy Unnatural Products, a Santa Cruz, California developer of macrocyclic peptides, for $550 million in cash upfront. The Argenx Unnatural Products acquisition adds up to $595 million in milestone payments, for a total potential value of about $1.15 billion, according to the companies' November 9 announcement as reported by trade outlets. Argenx said it wants the platform to produce oral or long acting medicines for serious immune mediated diseases. No drug programs or targets were named.
What Argenx agreed to pay
Argenx will fund the $550 million upfront payment from cash on hand, BioPharm International reported. The remaining $595 million depends on specified development and regulatory milestones. Pharmaceutical Technology described those payments as contingent value rights. The milestone triggers were not disclosed, so the full $1.15 billion may never be paid. Argenx already holds a minority stake in Unnatural Products and will buy the shares it does not own. The size of that stake has not been made public. The boards of both companies have approved the transaction. Argenx expects to complete the purchase before 2026 ends, once standard closing conditions are met. Both companies framed the Argenx Unnatural Products acquisition as the next step in a partnership that is now more than two years old.
That partnership took formal shape in July 2025. Under that multi target pact, Argenx won an exclusive option to develop and market oral macrocyclic peptides aimed at targets of its own choosing. Those terms made Unnatural Products eligible for option fees and milestone payments worth up to about $1.5 billion across the research, clinical, regulatory and sales stages, with royalties on top, BioPharm International reported. Argenx also agreed then to make an equity investment. The buyout replaces that option model with full ownership. Argenx will now control the platform itself rather than paying for individual programs as they advance. The table below sets out the announced terms. All figures are company disclosures, and the milestone portion is a ceiling, not a commitment. None of the figures depend on any drug reaching patients yet.
| Item | Detail |
|---|---|
| Announced | November 9, 2026 |
| Upfront cash | $550 million |
| Contingent milestones | Up to $595 million |
| Total potential value | About $1.15 billion |
| Expected close | By end of 2026 |
| Earlier tie | Multi target collaboration from July 2025 |
Why Argenx wants macrocyclic peptides
Argenx built its business on antibody engineering. Its flagship product, Vyvgart, was the first antibody fragment targeting the neonatal Fc receptor to reach the market, BioPharm International reported. Macrocyclic peptides are ring shaped chains of amino acids. Unnatural Products says they can bind protein targets once thought undruggable and may be given by mouth. Its platform combines machine learning guided design with parallel synthesis and direct to biology screening. "UNP adds macrocyclic peptide capabilities that are highly complementary to our antibody engineering and creates new possibilities for oral and long-acting medicines," Argenx chief executive Karen Massey said in the company statement. She added that the two firms share a working style that is "science first, entrepreneurial and focused on patients." Those are company claims about the platform, not trial findings.
Argenx is paying $550 million upfront for a discovery engine whose programs, targets and development stages have not been disclosed.
Argenx is paying $550 million upfront for a discovery engine whose programs, targets and development stages have not been disclosed. The platform has drawn other interest. Venture investors and large drugmakers including Merck & Co. and Novartis were also drawn to the technology, BioPharma Dive reported. After closing, the Unnatural Products team and its leaders will stay in Santa Cruz. The site will become the home of peptide discovery inside Argenx, according to the announcement. Unnatural Products will keep leading discovery work within a strategic framework agreed with Argenx. Argenx will supply clinical development and commercial capabilities. How the existing outside partnerships will be handled after the change of control was not described in the coverage reviewed for this story. That question matters for any partner programs already in progress.
Approved precedents for oral peptide drugs
Macrocyclic peptides are not new to regulators. The FDA has approved at least a handful, BioPharma Dive reported. Rhythm Pharmaceuticals' Imcivree was cleared in 2020 for certain genetic forms of obesity. Aurinia Pharmaceuticals' Lupkynis followed in 2021 as the first oral treatment approved for adults with active lupus nephritis. UCB's Zilbrysq won approval in 2023 for generalized myasthenia gravis. Two newer approvals involve peptides taken by mouth. In March 2026 the FDA cleared Johnson & Johnson's Icotyde, or icotrokinra, for plaque psoriasis, making it the first targeted peptide pill aimed at the IL-23 receptor. In July 2026 it approved Merck's Lipfendra, or enlicitide, a macrocyclic peptide that lowers LDL cholesterol. Pharmaceutical Technology reported that enlicitide is the first oral PCSK9 inhibitor, a target first reached with antibodies.
Oral peptide drugs still face hard chemistry. Peptides break down in the gut and cross the intestinal wall poorly. William Fang of WuXi AppTec told Pharmaceutical Technology that even when chemists tune the molecule and the formulation together, only a modest share of an oral peptide reaches the blood. Developers quoted in our coverage of oral peptide delivery work said each structural gain brings tradeoffs in potency, solubility and manufacturing. Some formulation experts are more upbeat. Karunakar Sukuru of Catalent told BioPharm International that "the oral delivery of peptides is clinically proven." He said highly potent peptides can work despite low absorption. The engineering behind the first GLP 1 pill shows the same tension. Whether the Unnatural Products platform eases these limits for immune targets has not been shown in published human data.
What the immunology pipeline deal leaves unknown
The deal sits beside a large commercial business. Vyvgart, which targets generalized myasthenia gravis, earned $4.5 billion in net product sales in the first nine months of 2026, BioPharma Dive reported. Myasthenia gravis has drawn several competing developers, including UCB with its peptide Zilbrysq. The Argenx Unnatural Products acquisition also follows its purchase of Forte Biosciences, a deal worth up to $2.2 billion. Leerink Partners analyst Thomas Smith wrote to clients that the new deal "represents potential for longer-term strategic value." He said drugmakers want oral, long acting immunology drugs that could beat standard biologics on both effect and convenience. Smith added that the deal "signals further focus on pipeline growth and diversification." Argenx shares gained nearly 3% by late Monday morning, trading near $953, BioPharma Dive reported.
Much remains unknown about this immunology pipeline bet. The announcement did not name any Unnatural Products program, molecular target, disease or development stage. It did not identify any candidate in clinical testing. The milestone triggers and the size of the existing minority stake are also undisclosed. Any medicines that come from the platform would need to pass clinical trials before regulators could weigh approval. Promises of oral or long acting drugs describe intent, not results. The next fixed point is closing, which Argenx expects by the end of 2026. After that, the first sign of progress would be a named program or a first in human study. Until then, the value of the deal rests on preclinical platform claims and the companies' own forecasts.
Conclusion
The Argenx Unnatural Products acquisition gives an antibody company full control of a macrocyclic peptide discovery platform for $550 million upfront and up to $595 million more. The terms come from company disclosures. The deal has not closed, no programs are public, and no candidate is known to be in human testing. Readers should watch for the closing, the first named target and any trial registration. This story is research news, not medical advice.
